NASDAQ:OPK - OPKO Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 93.80 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.58
▲ +0.07 (2.79%)

This chart shows the closing price for OPK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OPKO Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPK

Analyst Price Target is $5.00
▲ +93.80% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for OPKO Health in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a 93.80% upside from the last price of $2.58.

This chart shows the closing price for OPK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in OPKO Health. This rating has held steady since June 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/5/2022Piper SandlerLower Price TargetOverweight$5.00 ➝ $4.00Low
5/10/2022Piper SandlerLower Price Target$6.00 ➝ $5.00High
1/24/2022Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
1/18/2022Piper SandlerBoost Price Target$5.00 ➝ $6.00High
9/27/2021Barrington ResearchReiterated RatingBuy$6.00Low
9/24/2021Piper SandlerReiterated RatingBuy$5.00Low
7/30/2021Barrington ResearchLower Price TargetOutperform$8.00 ➝ $6.00Low
6/21/2021LADENBURG THALM/SH SHInitiated CoverageBuy$7.00Medium
2/19/2021Barrington ResearchBoost Price TargetOutperform$7.00 ➝ $8.00High
7/31/2020Piper SandlerBoost Price Target$6.00 ➝ $10.00High
7/31/2020Barrington ResearchReiterated RatingBuyMedium
7/8/2020Piper SandlerBoost Price Target$4.00 ➝ $6.00Medium
6/9/2020Piper SandlerBoost Price Target$3.00 ➝ $4.00High
6/8/2020Piper SandlerReiterated RatingBuy$3.00High
5/7/2020Barrington ResearchReiterated RatingBuy$4.00High
4/29/2020Piper SandlerReiterated RatingBuy$3.00Medium
3/10/2020Piper SandlerBoost Price Target$2.50 ➝ $3.00High
3/6/2020Piper SandlerReiterated RatingBuy$2.50 ➝ $3.00High
2/27/2020Barrington ResearchReiterated RatingBuy$4.00Medium
11/25/2019Piper Jaffray CompaniesInitiated CoverageOverweight$2.50High
9/12/2019Barrington ResearchReiterated RatingBuy$4.00Medium
2/28/2019Barrington ResearchReiterated RatingBuy$5.00Low
11/12/2018Barrington ResearchReiterated RatingBuy$7.00Medium
10/5/2018Barrington ResearchReiterated RatingBuy$7.00Low
8/7/2018Cantor FitzgeraldReiterated RatingBuy$20.00High
5/9/2018Barrington ResearchReiterated RatingBuy$7.00Medium
5/8/2018Cantor FitzgeraldReiterated RatingBuy$20.00High
3/2/2018JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$7.00High
3/1/2018Cantor FitzgeraldSet Price TargetBuy$20.00High
10/25/2017Cantor FitzgeraldSet Price TargetBuy$20.00N/A
10/12/2017Cantor FitzgeraldSet Price TargetBuy$20.00N/A
9/25/2017LADENBURG THALM/SH SHReiterated RatingBuy$16.00Medium
9/14/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$12.00 ➝ $7.00High
8/17/2017Cantor FitzgeraldInitiated CoverageOverweight$20.00Medium
8/10/2017Jefferies Financial GroupReiterated RatingHold$6.80 ➝ $6.50High
(Data available from 8/10/2017 forward)

News Sentiment Rating

-0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
1/12/2022
  • 7 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
2/11/2022
  • 7 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/13/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/12/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/12/2022
  • 4 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/11/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 4 very negative mentions
8/10/2022

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

OPKO Health logo
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $2.58
Low: $2.51
High: $2.60

50 Day Range

MA: $2.59
Low: $2.28
High: $3.09

52 Week Range

Now: $2.58
Low: $2.15
High: $5.25

Volume

32,387 shs

Average Volume

4,557,036 shs

Market Capitalization

$1.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75

Frequently Asked Questions

What sell-side analysts currently cover shares of OPKO Health?

The following sell-side analysts have issued stock ratings on OPKO Health in the last year: Barrington Research, Piper Sandler, StockNews.com, and TheStreet.
View the latest analyst ratings for OPK.

What is the current price target for OPKO Health?

2 Wall Street analysts have set twelve-month price targets for OPKO Health in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 99.2%. Barrington Research has the highest price target set, predicting OPK will reach $6.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $4.00 for OPKO Health in the next year.
View the latest price targets for OPK.

What is the current consensus analyst rating for OPKO Health?

OPKO Health currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OPK will outperform the market and that investors should add to their positions of OPKO Health.
View the latest ratings for OPK.

What other companies compete with OPKO Health?

How do I contact OPKO Health's investor relations team?

OPKO Health's physical mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company's listed phone number is (305) 575-4100 and its investor relations email address is [email protected] The official website for OPKO Health is www.opko.com. Learn More about contacing OPKO Health investor relations.